Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr Reddy's Laboratories has entered into a $56 million agreement with ICICI Venture, India's largest private equity investor, to expand its generic drugs pipeline for the US market.
Subscribe to our email newsletter
The agreement covers the development and commercialization of most of Dr Reddy’s abbreviated new drug applications (ANDAs) to be filed in 2004-05 and 2005-06.
Under the terms of the agreement, ICICI Venture will fund the development, registration and legal costs related to the commercialization of ANDAs on a pre-determined basis. On commercialization of these products, Dr Reddy’s will pay ICICI Venture royalty on net sales for a period of five years.
ICICI Venture will fund $22.5 million dollars in the first phase with an option to invest an additional $33.5 million dollars in the second phase.
Commenting on the partnership, GV Prasad, CEO of Dr Reddy’s, said, “We are pleased to partner with ICICI Ventures in what I believe is an unique R&D funding model. This model will enable us to share the product development costs while leveraging our global scale and infrastructure.”